Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML

Leuk Res. 2008 Feb;32(2):361-2. doi: 10.1016/j.leukres.2007.03.001. Epub 2007 Apr 6.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Mutation
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib